Skip to content

Brain Biomarker of Endogenous Analgesia in Patients With Chronic Knee Pain

Brain Biomarker of Endogenous Analgesia in Patients With Chronic Knee Pain

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05003323
Enrollment
110
Registered
2021-08-12
Start date
2021-11-18
Completion date
2023-10-20
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Chronic Knee Pain, Chronic Pain, Knee Osteoarthritis

Brief summary

This case-control study in patients with knee osteoarthritis and pain-free control individuals aims to develop a brain biomarker of endogenous analgesia that may be used in subsequent clinical trials. Deficits in central nervous system (CNS) pain inhibition may contribute to chronic pain intensity, but quantitative sensory testing (QST) methods are limited. Incorporating brain imaging to assessments of CNS pain inhibition, by examining activity in relevant brain networks, would allow for an objective, physiologic measure of CNS pain inhibition. Preliminary data in pain-free volunteers implicate cortical activity measured with functional near-infrared spectroscopy (fNIRS) during CNS pain inhibition. Broadly, the investigators hypothesize that variability in CNS pain inhibition contributes to variability in clinical pain intensity.

Detailed description

The objective of this study is to identify the neural correlates of central nervous system (CNS) pain inhibition in patients with knee osteoarthritis (OA) and determine how the correlates relate to clinical chronic (i.e., greater than 6 months) knee pain. To attain this objective, the investigators will test the following working hypotheses: (H1) in knee OA patients with moderate osteoarthritis but severe knee pain, cortical correlates of CNS pain inhibition are diminished compared to patients with less knee pain and (H2) provocation of clinical knee pain with ambulation produces greater pain-related cortical activation in patients with greater clinical knee pain at baseline. The study will also compare patients with knee OA to a control group to test the hypothesis (H3) that CNS pain inhibition behavioral and functional near-infrared spectroscopy (fNIRS) brain imaging measures are diminished in knee OA. Finally, in exploratory analysis, the investigators hypothesize that cortical functional connectivity is altered in patients with greater knee pain. The study approach is to measure brain activity in patients with knee osteoarthritis, divided into high pain intensity and low pain intensity groups, and in pain-free controls with fNIRS scanning during rest, quantitative sensory testing (QST) measures of CNS pain inhibition (conditioned pain modulation and offset analgesia), and walking and stair climbing tasks. The rationale is that successful completion of this study will determine whether fNIRS measures relate to QST measures of CNS pain inhibition and clinical pain intensity both at rest and during activity. This fundamental knowledge, in combination with prior studies of conditioned pain modulation (CPM), will be important to understanding how CNS pain inhibition may contribute to a range of chronic pain syndromes.

Interventions

None listed

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. For the knee arthritis groups: Chronic knee pain with evidence of knee osteoarthritis - radiographically grades 2-4 2. Age: 45-80 years old 3. Gender: Males and females will be recruited. 4. Language: only English-speaking subjects will be included.

Exclusion criteria

1. Inflammatory arthritis (e.g. rheumatoid arthritis) 2. Inability to walk and climb stairs unassisted 3. History of knee replacement or open knee surgery 4. History of arthroscopic knee surgery within the last 3 months (\>3 months does not exclude participant) 5. History of knee radiofrequency nerve ablation or ligation 6. Current opioid use 7. Current use of antidepressants that are not in the serotonin-selective reuptake inhibitor (SSRI) class. Patients who are currently using an SSRI are allowed to take part in the study 8. Cognitive impairment affecting the ability to provide informed consent, understand directions, and participate in study procedures 9. Uncontrolled or unstable medical disorder preventing participation in study procedures 10. History of brain surgery 11. Tattoos on forearm or knee 12. Pregnancy 13. Patients with chronic pain conditions that are more severe than their knee arthritis pain (e.g., CRPS, fibromyalgia) 14. Patients whose most painful knee is excluded for another reason (e.g., recent surgery on most painful knee) 15. For the pain-free control group: a history of chronic pain 16. History of intra-articular steroid injections, platelet enriched or hyaluronic acid injections in the last 1 month

Design outcomes

Primary

MeasureTime frameDescription
Differences in offset analgesia15 minutesPain intensity difference during offset and control heat stimuli
Differences in brain region activation- QST2-3 hoursDifference in brain region activation (as measured by oxygenated hemoglobin, HbO) between CNS inhibition and control stimuli during QST procedures.
Differences in brain region activation- walking test15 minutesChange in brain region activation (HbO) between rest and ambulation during the 6 minute walking test test
Differences in brain region activation- stair climbing15 minutesChange in brain region activation (HbO) between rest and ambulation during the stair climbing test

Secondary

MeasureTime frameDescription
Duration of stair climbing task10 minutesDifferences in time taken to complete stair climbing task
Distance walked during 6 minute walking task6 minutesDifferences in distance walked during 6 minute walking task
Questionnaire score- PROMIS 291 hourStandardized survey score of PROMIS-29 assessing physical and mental health. Physical Function Score ranges from 4-20. Anxiety Score ranges from 4-20. Depression Score ranges from 4-20. Fatigue Score ranges from 4-20. Sleep Disturbance Score ranges from 4-20. Social Roles Score ranges from 4-20. Pain Interference Score ranges from 4-20. Pain Intensity Score ranges from 0-10. Higher scores indicate worse mental and physical health.
Questionnaire score- Knee Injury and Osteoarthritis Outcome Score (KOOS)1 hourStandardized survey called Knee Injury and Osteoarthritis Outcome Score assessing knee pain. Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms.
Questionnaire score- State Trait Anxiety Inventory (STAI) Y1-21 hourStandardized survey score of state trait anxiety inventory Y1 and Y2 assessing anxiety before QST procedures. State Anxiety Score ranges from 20-80. Trait Anxiety Score ranges from 20-80. Higher scores indicate worse anxiety state and trait symptoms.
Questionnaire score- Pain Catastrophizing Scale (PCS)1 hourStandardized survey score assessing pain perception before QST procedures. Rumination subscale score ranges from 0-16. Magnification subscale score ranges 0-12. Helplessness subscale score ranges from 0-24. Total score can be calculated by summing subscales. Total score ranges from 0-52, with higher scores indicating more pain catastrophizing.
Questionnaire score- STAI Y1 post testing1 hourStandardized survey score of state trait anxiety inventory Y1 assessing anxiety immediately after QST procedures. Higher scores indicate worse anxiety state.
Differences in resting fNIRS signaling5-10 minutesDifferences in fNIRS resting state connectivity as measured by brain region activation
Questionnaire score- Situational Pain Catastrophizing Scale post mobility tasks1 hourStandardized survey score assessing pain perception immediately after walking and stair climbing tasks are completed. Scores range from 0-24, with higher scores representing more pain catastrophizing.
Questionnaire score- Beck Depression Inventory-II (BDI-II)1 hourStandardized survey assessing depression. Scores range from 0-63. Total score of 0-13 is considered minimal range of depression, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depression.
Questionnaire score- Generalized Anxiety Disorder 2-item (GAD-2)1 hourStandardized survey score of GAD-2 assessing anxiety. Scores range from 0-6. Higher scores indicate higher likelihood of having GAD.
Questionnaire score- Barratt Impulsiveness Scale-111 hourStandardized survey score of Barratt Impulsiveness Scale-11 assessing the personality/behavioral construct of impulsiveness. Attention Impulsiveness Score ranges from 8-32. Motor Impulsiveness Score ranges from 11-44. Non-planning Impulsiveness Score ranges from 11-44. Subscale scores can be summed for a total score. Higher scores indicate greater levels of impulsivity.
Questionnaire score- Barratt Simplified Measure of Social Status1 hourStandardized survey score of Barratt Simplified Measure of Social Status that measures social status based on marital status, employment status, educational attainment, and occupational prestige. Total Education Score ranges from 3-21. Total Occupation Score ranges from 5-45. Total score of education and occupation can be calculated by summing the subscales with a range 8-66. Higher scores indicate a higher social status.
Questionnaire score- Patient Health Questionnaire 2 (PHQ-2)1 hourThe PHQ-2 inquires about the frequency of depressed mood and anhedonia over the past two weeks. The PHQ-2 includes the first two items of the PHQ-9. A PHQ-2 score ranges from 0-6. The authors identified a score of 3 as the optimal cutpoint when using the PHQ-2 to screen for depression. If the score is 3 or greater, major depressive disorder is likely.
Questionnaire score- Fibromyalgia Severity Scale1 hourThis questionnaire tests if patients meet the 2016 criteria for fibromyalgia. The symptom severity score ranges from 0-12, with higher scores indicating a higher likelihood of fibromyalgia. Three symptom question items range from 0-3, and these are summed up for the final score (totaling 0-9). Three additional symptom questions have yes or no options. If the patient answers yes, 1 point is added to the final scale.
Questionnaire score- Situational Pain Catastrophizing Scale post testing1 hourStandardized survey score assessing pain perception immediately after QST procedures are completed. Scores range from 0-24, with higher scores representing more pain catastrophizing.
QST battery responses2-3 hoursDifferences in responses to QST to characterize threshold and tolerance to cutaneous thermal and mechanical stimuli
Pain intensity scores after stair climbing task10 minutesVerbal score from 0-100 on numeric rating scale (NRS) of pain following stair climbing task. Higher NRS scores indicate higher pain intensity.
Pain intensity scores after walking test6 minutesVerbal score from 0-100 on NRS of pain following 6 minute walking task. Higher NRS scores indicate higher pain intensity.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026